Friday, May 15, 2026 | 6:00 PM-7:30 PM CDT
The Marriott Rivercenter, San Antonio, TX | Grand Ballroom GHI
Learn from Leaders | Connect with Peers
MLI Dialogues | Nursing Perspectives in Myelodysplastic Syndromes: Risk-Adapted Therapy and Symptom Management at ONS 2026
Myelodysplastic syndromes present unique challenges for oncology nurses. From navigating complex risk stratification systems to managing evolving treatment regimens and supporting patients through difficult symptom burdens.
Unlike traditional lectures, this Dialogues symposium format brings attendees into the conversation. Through real-time audience interaction, multidisciplinary expert insights, and real-world patient cases, you’ll explore the complexities of MDS alongside leading specialists in an engaging, studio-quality format. This ONS-partnered program (MLI Dialogues) delivers interactive, expert-led education that translates the latest advances into actionable nursing approaches, empowering you to improve patient adherence, enhance quality of life, and deliver comprehensive, risk-adapted care with confidence.
Meet Our Faculty
Ilene Galinsky BSN, MSN, NPc
Senior Program Research Nurse
the Adult Leukemia Division Dana Farber Cancer Institute
Boston, MA, USA
Selena Carmona MS, MPAS, PA-C
Physician Assistant
Clinics of Dr. Gautam Borthakur/Dr. Guillermo Garcia Manero, Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
Kristi K. Orbaugh, MSN, NP, AOCNP
Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, IN, USA
In-Person & Virtual Registration
ONS Registration NOT Required to Participate Virtually
If you’re unable to attend in-person, this ONS session will also be available via live stream on MLI’s social channels and Zoom. Learners can earn credit for FREE if you join the session via the live stream options.
Register below to receive updates about this upcoming session
This activity is designed for US-based nurses, NPs, and PAs who work with patients with hematologic malignancies.
- Welcome and Introduction
- Risk Stratification in MDS: What Oncology Nursing Professionals Should Know
- Equipping Oncology Nurses with Cutting-Edge Tools for the Management of Patients with LR MDS and HR MDS
- Recognition and Management of Treatment-Related Adverse Events and Disease-Related Symptoms Across MDS Care Settings
- Empowering Nurses to Facilitate Shared Decision-Making in LR MDS and HR MDS Care
- Conclusions
After completing this activity, the participant should be better able to:
- Explain key clinical factors and cytogenetic/molecular biomarkers used in risk stratification and management of patients with lower-risk myelodysplastic syndrome (LR MDS) and higher-risk myelodysplastic syndrome (HR MDS)
- Apply current and emerging therapeutic options for the management of anemia in patients with LR MDS, based on the latest data and evidence-based guidelines
- Develop monitoring and management strategies for treatment-related adverse events and disease-related complications in patients with LR MDS
- Implement nursing-led approaches to educate and counsel patients with LR MDS and equip them for productive shared decision-making encounters
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 0.75 contact hour in the area of pharmacology.
ILNA
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
In the following ILNA subject areas:
0.5 points: Foundations of Transplant/HSCT and Cellular Therapy (TCTCN); Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP); Treatment (AOCNP, CBCN, CPHON, OCN, ROCN)
1.25 points: Oncology Nursing Practice (OCN); Pediatric Hematology Oncology Nursing Practice (CPHON)
The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.
PA
MMedical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change
MIPS
Completion of this accredited CE activity will meet the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Support Statement
This activity is supported by educational grants from Bristol Myers Squibb and Geron Corporation.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Ilene Galinsky, BSN, MSN, NPc, has no relevant financial relationships with ineligible companies to disclose for this educational activity.ona
Planner/Presenter
Selena Carmona, MS, MPAS, PA-C, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Kristi Orbaugh, MSN, NP, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speaker: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Pfizer, Sanofi, Sobi, Stemline
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.
This activity is supported by educational grants from Bristol Myers Squibb and Geron Corporation.